Skip Nav Destination
Issues
1 August 2012
-
Cover Image
Cover Image
The recently discovered recurrent ERG rearrangement is highly specific for prostate cancer. There are significant associations of ERG rearrangement in preoperative biopsies with pelvic lymph node metastasis for patients with prostate cancer. The fluorescence in situ hybridization image shows representative nuclei of a prostate cancer gland. One yellow/one green/one red in a nucleus represents abnormal signal patterns indicative of an ERG rearrangement. For details, please see the article by Gao and colleagues on page 4163 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Statistics in Clinical Cancer Research
Molecular Pathways
Human Cancer Biology
Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
Katja Harbst; Johan Staaf; Martin Lauss; Anna Karlsson; Anna Måsbäck; Iva Johansson; Pär-Ola Bendahl; Johan Vallon-Christersson; Therese Törngren; Henrik Ekedahl; Jürgen Geisler; Mattias Höglund; Markus Ringnér; Lotta Lundgren; Karin Jirström; Håkan Olsson; Christian Ingvar; Åke Borg; Hensin Tsao; Göran Jönsson
Cancer Therapy: Preclinical
Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
Gaspar J. Kitange; Ann C. Mladek; Brett L. Carlson; Mark A. Schroeder; Jenny L. Pokorny; Ling Cen; Paul A. Decker; Wenting Wu; Gwen A. Lomberk; Shiv K. Gupta; Raul A. Urrutia; Jann N. Sarkaria
IGKV3 Proteins as Candidate “Off-the-Shelf” Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas
Debora Martorelli; Massimo Guidoboni; Valli De Re; Elena Muraro; Riccardo Turrini; Anna Merlo; Elisa Pasini; Laura Caggiari; Luca Romagnoli; Michele Spina; Roberta Mortarini; Daniela Gasparotto; Mario Mazzucato; Antonino Carbone; Antonio Rosato; Andrea Anichini; Riccardo Dolcetti
Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
Changgeng Qian; Cheng-Jung Lai; Rudi Bao; Da-Gong Wang; Jing Wang; Guang-Xin Xu; Ruzanna Atoyan; Hui Qu; Ling Yin; Maria Samson; Brian Zifcak; Anna Wai See Ma; Steven DellaRocca; Mylissa Borek; Hai-Xiao Zhai; Xiong Cai; Maurizio Voi
Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
Sun Joo Lee; Sukhen C. Ghosh; Hee Dong Han; Rebecca L. Stone; Justin Bottsford-Miller; De Yue Shen; Edmond J. Auzenne; Alejandro Lopez-Araujo; Chunhua Lu; Masato Nishimura; Chad V. Pecot; Behrouz Zand; Duangmani Thanapprapasr; Nicholas B Jennings; Yu Kang; Jie Huang; Wei Hu; Jim Klostergaard; Anil K. Sood
Imaging, Diagnosis, Prognosis
Progenitor-like Traits Contribute to Patient Survival and Prognosis in Oligodendroglial Tumors
Felicia Soo-Lee Ng; Tan Boon Toh; Esther Hui-Ling Ting; Geraldene Rong-Hui Koh; Edwin Sandanaraj; Mark Phong; Swee Seong Wong; Siew Hong Leong; Oi Lian Kon; Greg Tucker-Kellogg; Wai Hoe Ng; Ivan Ng; Carol Tang; Beng Ti Ang
ERG Rearrangement for Predicting Subsequent Cancer Diagnosis in High-Grade Prostatic Intraepithelial Neoplasia and Lymph Node Metastasis
Xin Gao; Liao-Yuan Li; Fang-Jian Zhou; Ke-Ji Xie; Chun-Kui Shao; Zu-Lan Su; Qi-Peng Sun; Ming-Kun Chen; Jun Pang; Xiang-Fu Zhou; Jian-Guang Qiu; Xing-Qiao Wen; Ming Yang; Xian-Zhong Bai; Hao Zhang; Li Ling; Zhong Chen
Cancer Therapy: Clinical
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
David S. Hong; Daniel W. Bowles; Gerald S. Falchook; Wells A. Messersmith; Goldy C. George; Cindy L. O'Bryant; Alex C. H. Vo; Kevin Klucher; Roy S. Herbst; S. Gail Eckhardt; Scott Peterson; Diana F. Hausman; Razelle Kurzrock; Antonio Jimeno
Predictive Biomarkers and Personalized Medicine
Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Yoshinori Ito; Hiroshi Kimura; Yoshinobu Maeda; Chizuko Hashimoto; Fumihiro Ishida; Koji Izutsu; Noriyasu Fukushima; Yasushi Isobe; Jun Takizawa; Yuichi Hasegawa; Hajime Kobayashi; Seiichi Okamura; Hikaru Kobayashi; Motoko Yamaguchi; Junji Suzumiya; Rie Hyo; Shigeo Nakamura; Keisei Kawa; Kazuo Oshimi; Ritsuro Suzuki
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration
Ke Lin; Janet Adamson; Gillian G. Johnson; Anthony Carter; Melanie Oates; Rachel Wade; Sue Richards; David Gonzalez; Estella Matutes; Claire Dearden; David G. Oscier; Daniel Catovsky; Andrew R. Pettitt
TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
Lai Ling Cheng; Yoko Itahana; Zheng Deng Lei; Na-Yu Chia; Yonghui Wu; Yingnan Yu; Shen Li Zhang; Aye Aye Thike; Anuradha Pandey; Steve Rozen; Pieter Mathijs Voorhoeve; Qiang Yu; Puay Hoon Tan; Boon Huat Bay; Koji Itahana; Patrick Tan
Letters to the Editor
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.